A single line often inverts meaning once you see what it
answers, so neighbouring messages are always shown.
-
What's the point?
-
I'm going to get to that. So if you go back to the NSABB P3CO regulations, the regulations state that viruses, like flu, SARS, and MERS coronavirus, are highly pathogenic viruses, and highly transmissible viruses are covered by this program. And if you do anything on these particular viruses that are highly pathogenic or highly transmissible, and you do any manipulation to increase that, then that's considered gain-of-function and regulated by those documents, based on my read of them. There are exemptions to that gain-of-function regulation framework. The first is that if you work with zoonotic viruses, like WIV1, which has never been show to infect a human being, that has never shown to be transmissible in humans, it is not subject to the gain-of18 function regulatory framework. It has to be reviewed, but the review process would require that it be -- the review process would, based on the regulations, say it's not subject to those gain --
-
But how do you know what you don't know?
-
Secondly, if you're doing work that's related to the development of vaccines or serology, it's also except from the gain-of-function policy. DC.Scheduling@LexitasLegal.com
-
2026-04-10 09:00
Christina Salazar
Or national security. That was also an exemption.
-
I don't know what you mean by that.
-
Yeah. I'm just saying it was. I wasn't --
-
So anyway, all the work with pseudotypes was not subject to gain, right. These are single-hit vectors that can't cause disease. As soon as we made full molecular clones, or chimeras, they were done in a WIV backbone, which meant that they're putting a zoonotic spike into a zoonotic strain, to eventually identify vaccine formulations that would be used in the cave, that's not subject to gain-of-function.
-
It's not.